{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:13:39Z","timestamp":1791980019421,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K16022"],"award-info":[{"award-number":["JP21K16022"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejim.2024.04.012","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T03:37:29Z","timestamp":1714016249000},"page":"74-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Direct oral anticoagulant-associated bleeding complications in patients with gastrointestinal cancer and venous thromboembolism"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-8540","authenticated-orcid":false,"given":"Yuji","family":"Nishimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-1321","authenticated-orcid":false,"given":"Yugo","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6844-739X","authenticated-orcid":false,"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuki","family":"Chatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4329-5975","authenticated-orcid":false,"given":"Kazuhisa","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1615-3736","authenticated-orcid":false,"given":"Nobutaka","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8163-8038","authenticated-orcid":false,"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5751-5775","authenticated-orcid":false,"given":"Kitae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-4899","authenticated-orcid":false,"given":"Moriaki","family":"Inoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihito","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-1924","authenticated-orcid":false,"given":"Masatake","family":"Fukunami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-4076","authenticated-orcid":false,"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2024.04.012_bib0001","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.04.012_bib0002","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/bloodadvances.2021005590","article-title":"The incidence of cancer-associated thrombosis is increasing over time","volume":"6","author":"Mahajan","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejim.2024.04.012_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.26930","article-title":"Trends in imaging for suspected pulmonary embolism across US Health Care Systems, 2004 to 2016","volume":"3","author":"Wang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejim.2024.04.012_bib0004","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2024.04.012_bib0005","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1055\/a-1886-5991","article-title":"Treatment and bleeding complications of cancer-associated venous thromboembolism: a korean population-based study","volume":"122","author":"Kim","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.04.012_bib0006","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028981","article-title":"Trends in treatment patterns and outcomes of patients with pulmonary embolism in Japan, 2010 to 2020: a nationwide inpatient database study","volume":"12","author":"Nishimoto","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2024.04.012_bib0007","first-page":"1203","article-title":"How to choose an appropriate anticoagulant for cancer-associated thrombosis","volume":"19","author":"Schaefer","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejim.2024.04.012_bib0008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor's choice - European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis","volume":"61","author":"Kakkos","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejim.2024.04.012_bib0009","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.04.012_bib0010","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2024.04.012_bib0011","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1253\/circj.CJ-19-0515","article-title":"Cancer-associated venous thromboembolism in the real world- from the COMMAND VTE registry","volume":"83","author":"Sakamoto","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2024.04.012_bib0012","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1055\/s-0041-1735194","article-title":"Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer","volume":"122","author":"Agnelli","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.04.012_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001885","article-title":"The reporting of studies conducted using observational routinely-collected health data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejim.2024.04.012_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2023.08.007","article-title":"Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants","author":"Kaneda","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2024.04.012_bib0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.04.012_bib0016","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.04.012_bib0017","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Investigators","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.04.012_bib0018","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2022.09.002","article-title":"Causes of long-term mortality in patients with venous thromboembolism in the real world: from the COMMAND VTE registry","volume":"219","author":"Yamashita","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2024.04.012_bib0019","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jaccao.2022.08.002","article-title":"Considerations of competing risks analysis in cardio-oncology studies: JACC: cardioOncology state-of-the-art review","volume":"4","author":"Li","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.ejim.2024.04.012_bib0020","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejim.2024.04.012_bib0021","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2024.04.012_bib0022","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1111\/jth.15776","article-title":"Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: communication from the ISTH SSC subcommittee on predictive and diagnostic variables in thrombotic disease","volume":"20","author":"den Exter","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.04.012_bib0023","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1253\/circj.CJ-20-0223","article-title":"Risk factors for major bleeding during anticoagulation therapy in cancer-associated venous thromboembolism \u2013 from the COMMAND VTE registry","volume":"84","author":"Nishimoto","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2024.04.012_bib0024","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.04.012_bib0025","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2024.04.012_bib0026","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.04.012_bib0027","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.04.012_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103074","article-title":"Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: a systematic review and meta-analysis","volume":"154","author":"Camilli","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejim.2024.04.012_bib0029","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaccao.2023.10.009","article-title":"Comparing anticoagulation strategies for venous thromboembolism associated with active cancer: a systematic review and meta-analysis","volume":"6","author":"Fujisaki","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.ejim.2024.04.012_bib0030","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study","volume":"118","author":"Kraaijpoel","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.04.012_bib0031","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1055\/s-0040-1720975","article-title":"Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the caravaggio study","volume":"121","author":"Ageno","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.04.012_bib0032","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2023.02.003","article-title":"Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism","volume":"112","author":"Vedovati","year":"2023","journal-title":"Eur J Internal Med"},{"key":"10.1016\/j.ejim.2024.04.012_bib0033","article-title":"Early time courses of recurrent venous thromboembolism and bleeding during apixaban or dalteparin therapy for patients with cancer","author":"Cohen","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.04.012_bib0034","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jaccao.2023.09.003","article-title":"Cancer-associated thrombosis: trends in clinical features, treatment, and outcomes from 2001 to 2020","volume":"5","author":"Bertoletti","year":"2023","journal-title":"JACC CarioOncol"},{"key":"10.1016\/j.ejim.2024.04.012_bib0035","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1538-7836.2010.03852.x","article-title":"Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry","volume":"8","author":"Nieto","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.04.012_bib0036","doi-asserted-by":"crossref","first-page":"e1235","DOI":"10.1097\/MD.0000000000001235","article-title":"Fatal events in cancer patients receiving anticoagulant therapy for venous thromboembolism","volume":"94","author":"Farge","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejim.2024.04.012_bib0037","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2022.04.005","article-title":"Major gastrointestinal bleeding in patients receiving anticoagulant therapy for venous thromboembolism","volume":"214","author":"Catella","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2024.04.012_bib0038","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/jth.14007","article-title":"Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study","volume":"16","author":"Kamphuisen","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2024.04.012_bib0039","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjmed.2016.10.017","article-title":"The clinical course of venous thromboembolism may differ according to cancer site","volume":"130","author":"Mah\u00e9","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2024.04.012_bib0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.thromres.2019.11.007","article-title":"Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study","volume":"185","author":"Mulder","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2024.04.012_bib0041","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.04.012_bib0042","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.04.012_bib0043","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0040-1708481","article-title":"A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer","volume":"120","author":"Abdulla","year":"2020","journal-title":"Thromb Haemost"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524001717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524001717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T18:58:14Z","timestamp":1726340294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524001717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":43,"alternative-id":["S0953620524001717"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.04.012","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulant-associated bleeding complications in patients with gastrointestinal cancer and venous thromboembolism","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}